Introducing Project Prima Donna: the first-ever treatment designed to regenerate lost enamel to keep you smiling for a lifetime. Enamel erosion is an irreversible, age-related condition that no one is immune from, leading to tooth sensitivity, cavities, and more severe health complications. Current solutions, such as fluoride rinses, crowns, or veneers, merely mask the problem without addressing the root cause. Spearheaded by renowned stem cell researchers and dentists Dr. Hannele Ruohola-Baker, Dr. Julie Mathieu, and Dr. Jonathan An, this project utilizes breakthroughs in induced pluripotent stem cell (iPSC) technology to develop enamel-regenerating organoids. These organoids have shown promising results in the lab and are now ready for testing in a relevant animal model. This is an important step towards developing a drug that can move us beyond mere symptom management, to restore our natural ability to produce enamel. The global economic burden of poor oral health was estimated to be $544 billion in 2015, and oral health is the most prevalent non-transmissible disease worldwide. If successful, this treatment stands to significantly reduce the global burden of dental diseases and healthcare costs. Join us on our journey to revolutionize oral health and to create a future where aging never dims your brilliant smile.
Introducing Project Prima Donna: the first-ever treatment designed to regenerate lost enamel to keep you smiling for a lifetime. Enamel erosion is an irreversible, age-related condition that no one is immune from, leading to tooth sensitivity, cavities, and more severe health complications. Current solutions, such as fluoride rinses, crowns, or veneers, merely mask the problem without addressing the root cause.
Spearheaded by renowned stem cell researchers and dentists Dr. Hannele Ruohola-Baker, Dr. Julie Mathieu, and Dr. Jonathan An, this project utilizes breakthroughs in induced pluripotent stem cell (iPSC) technology to develop enamel-regenerating organoids. These organoids have shown promising results in the lab and are now ready for testing in a relevant animal model. This is an important step towards developing a drug that can move us beyond mere symptom management, to restore our natural ability to produce enamel.
The global economic burden of poor oral health was estimated to be $544 billion in 2015, and oral health is the most prevalent non-transmissible disease worldwide. If successful, this treatment stands to significantly reduce the global burden of dental diseases and healthcare costs. Join us on our journey to revolutionize oral health and to create a future where aging never dims your brilliant smile.
Dr Hannele Ruohola-Baker
Research Lead
Time | Type | $DONNA | USD | ETH | From |
|---|---|---|---|---|---|
Therapeutic Relevance
Clear MoA recapitulating amelogenesis; in vivo enamel-like mineralization validates therapeutic…
Therapeutic Optionality
Amelogenesis imperfecta disease model adds optionality, but applications remain dental-specific.
Intellectual Property
PCT filed with strong inventor list, but scope of protection and FTO assessment not addressed.
Utility Of Candidates
Organoids show functional protein expression and in vivo mineralization, but dose-finding…
Prospects For Safety
No safety or toxicology data reported; only immunodeficient mouse model used so far.
Prospects For Gmp Cmc
Protocols standardized but scale-up targets unmet; cryopreservation and GMP readiness unaddressed.
Prospects For Clinical Development
No regulatory pathway, clinical endpoints, or FDA strategy defined; very early stage.
Commercial Potential
Massive $120B US dental market with 2.4B affected patients and no regenerative competitors.
Organization And Team Fit
Strong academic team including David Baker; trained personnel and reproducible workflows…